Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. It is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Haduvio is an oral extended-release (ER) formulation of nalbuphine. It is conducting Phase IIb/3 clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It is also conducting Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as Phase II CANAL trial. It has also commenced Phase Ib trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio. Its Haduvio development programs include Active Chronic Pruritus Programs, Prurigo Nodularis Program, and Chronic Cough in Idiopathic Pulmonary Fibrosis Program.